Geode Capital Management
ARDS

Geode Capital Management’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Geode Capital Management’s Portfolio ARDS Stock Details ARDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-143,034
Closed -$31.5K – 4879
2023
Q2 		$31.5K Hold
143,034
– – ﹤0.01% 4593
2023
Q1 		$44.9K Hold
143,034
– – ﹤0.01% 4546
2022
Q4 		$168K Buy
143,034
+7,013
+5% +$6.77K ﹤0.01% 4193
2022
Q3 		$126K Buy
136,021
+25,821
+23% +$40.2K ﹤0.01% 4455
2022
Q2 		$121K Buy
110,200
+3,561
+3% +$4.42K ﹤0.01% 4508
2022
Q1 		$187K Buy
106,639
+68,665
+181% +$130K ﹤0.01% 4417
2021
Q4 		$88K Buy
37,974
+2,075
+6% +$5.9K ﹤0.01% 4762
2021
Q3 		$132K Buy
+35,899
New +$166K ﹤0.01% 4597

Other funds holding ARDS

WA
Wealth Architects Mountain View, California $1.27B AUM 36.93% 1-Year Est. Return

Geode Capital Management's ARDS Position: Q3 2023 in Review

Geode Capital Management sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2023, closing a stake of 143,034 shares — an estimated $31.5K sold.

Geode Capital Management first reported a position in ARDS in Q3 2021 and held it in 8 quarters. The position peaked at $187K in Q1 2022. 1 fund tracked by Wall St. Rank holds ARDS as of Q3 2023.

  • Geode Capital Management reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Geode Capital Management sold 143,034 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $31.5K.
  • Geode Capital Management first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 8 quarters.
  • Geode Capital Management's Aridis Pharmaceuticals Inc. Common Stock position peaked at $187K in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2023.

Based on Geode Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.